Schonfeld Strategic Advisors LLC Bio N Tech Se Transaction History

Schonfeld Strategic Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$90.91 - $112.75 $1.03 Million - $1.28 Million	11,377 Added 494.65%	13,677 $1.44 Million
Q3 2023 Nov 14, 2023	SELL	$98.5 - $125.08 $7.82 Million - $9.93 Million	-79,398 Reduced 97.18%	2,300 $249,000
Q2 2023 Aug 14, 2023	BUY	$102.58 - $129.66 $8.38 Million - $10.6 Million	81,698 New	81,698 $8.82 Million
Q4 2022 Feb 14, 2023	BUY	$118.43 - $186.05 $1.43 Million - $2.25 Million	12,080 New	12,080 $1.81 Million
Q2 2022 Aug 15, 2022	BUY	$123.25 - $186.24 $4.29 Million - $6.48 Million	34,795 New	34,795 $5.19 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $404,000 - $741,920	-3,200 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $693,248 - $1.16 Million	3,200 New	3,200 $825,000
Q1 2021 May 17, 2021	SELL	$85.73 - $119.5 $1.02 Million - $1.42 Million	-11,900 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$72.71 - $129.54 $648,282 - $1.15 Million	-8,916 Reduced 42.83%	11,900 $970,000
Q3 2020 Nov 16, 2020	SELL	$57.81 - $104.17 $1.95 Million - $3.52 Million	-33,784 Reduced 61.88%	20,816 $1,000
Q2 2020 Aug 14, 2020	BUY	$38.58 - $66.74 $2.11 Million - $3.64 Million	54,600 New	54,600 $3.64 Million

357

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $29.3B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.